Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020115045 - DÉRIVÉS DE 1H-BENZO[D]IMIDAZOLE SUBSTITUÉS AYANT UNE ACTIVITÉ MULTIMODALE DIRIGÉE CONTRE LA DOULEUR ET DES ÉTATS PATHOLOGIQUES ASSOCIÉS À LA DOULEUR


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2019/083499 ESTA-1812/WO
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
03 December 2019 05 December 2018
Applicant
ESTEVE PHARMACEUTICALS, S.A.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C07D 401/14 (2006.01)i; C07D 401/06 (2006.01)i; C07D 235/14 (2006.01)i; C07D 403/06 (2006.01)i; A61K 31/496 (2006.01)i; A61K 31/551 (2006.01)i; A61P 25/02 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C07D; A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2013101926 A1 (ALLERGAN INC [US]; EHRING GEORGE R [US]; GARST MICHAEL E [US]; AVEY JR) 04 July 2013 (2013-07-04)
1-4,8-15
A
Whole document, specially claims 3-6 and 21, p. 42-44
5-7
(2)
A
XIAO JIAN WANG ET AL, "Synthesis, biological evaluation and SAR studies of benzimidazole derivatives as H1-antihistamine agents", CHINESE CHEMICAL LETTERS,Vol. 23, No. 6, 01 June 2012 (2012-06-01), page 707-710,
XP055545405
1-15
compounds 17e and 17f and BOC protected derivatives thereof
(3)
X
WO 2012116440 A1 (ZALICUS PHARMACEUTICALS LTD [CA]; PAJOUHESH HASSAN [CA]; HOLLAND RICHA) 07 September 2012 (2012-09-07)
1-4,8-15
A
claims 1, 3, 105-117. compounds 122-123, 135-137, 142
5-7
(4)
A
SU JIN GU ET AL, "Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,Vol. 20, No. 9, 01 May 2010 (2010-05-01), page 2705-2708,
XP055545456
1-15
Whole document, particularly compounds 4a-s, 9a-s and Table 2
(5)
A
WO 2010111948 A1 (UNIV CHINA PHARMA [CN]; YOU QIDONG [CN]; YANG QIAN [CN]; WANG XIAOJIAN) 07 October 2010 (2010-10-07)
1-15
claims 1 and 8 and compounds 1-11, 14-15, 24
(6)
X
Magar Vidya ET AL, "ISSN: 0975-766X CODEN: IJPTFI DOCKING, SYNTHESIS AND EVALUATION OF ANTIFUNGAL ACTIVITY OF 5- CHLORO-1-ISOPROPYL-2-[1-(4-ALKYL/ARYLPIPERAZIN-1-YL) ETHYL]-1H BENZIMIDAZOLES", 01 September 2017 (2017-09-01), page 30800-30826,
Retrieved from the Internet:
URL:http://www.ijptonline.com/wp-content/uploads/2017/10/30800-30826.pdf
XP055666835
[retrieved on  2020-02-10]
1-4,9,11,12,15
compounds 3 and 4 in Table 3, p. 30808
(7)
X
RANI S KANKATE ET AL, "Synthesis and in vitro antifungal evaluation of benzoimidazolyl-piperazinyl-phenylmethanone derivatives.", ORIENTAL JOURNAL OF CHEMISTRY,Vol. 30, No. 4, 31 December 2014 (2014-12-31), page 1855-1863,
XP055666870
1-3,10-12,15
compounds 11e, 11h
(8)
X
Rani S Kankate ET AL, "Microwave assisted synthesis, antifungal evaluation and moleculer docking of benzimidazole derivatives", 01 January 2014 (2014-01-01), page 396-405,
Retrieved from the Internet:
URL:https://www.derpharmachemica.com/pharma-chemica/microwave-assisted-synthesis-antifungal-evaluation-and-moleculer-docking-of-benzimidazole-derivatives.pdf
XP055666885
1-3,10-12,15
compounds 10e and 10h
(9)
X
WO 03060475 A2 (NEUROGEN CORP [US]; DE SIMONE ROBERT [US] ET AL.) 24 July 2003 (2003-07-24)
1-3,9,11,12,15
compound 58 in p. 44; claims 14, 25
(10)
X
WO 0194317 A2 (ORTHO MCNEIL PHARM INC [US]) 13 December 2001 (2001-12-13)
1,2,4
compounds with ID#42 and 66 in Table 3
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2013101926 A1
04 July 2013
EP 2797896 A1
US 2013172342 A1
WO 2013101926 A1
05 November 2014
04 July 2013
04 July 2013
WO 2012116440 A1
07 September 2012
CA 2828456 A1
EP 2681200 A1
EP 3009427 A1
US 2014187533 A1
US 2015361032 A1
US 2017260130 A1
US 2018111894 A1
WO 2012116440 A1
07 September 2012
08 January 2014
20 April 2016
03 July 2014
17 December 2015
14 September 2017
26 April 2018
07 September 2012
WO 2010111948 A1
07 October 2010
CN 101503392 A
WO 2010111948 A1
12 August 2009
07 October 2010
WO 03060475 A2
24 July 2003
CA 2473236 A1
EP 1465635 A2
JP 2005532991 A
US 2003229074 A1
WO 03060475 A2
24 July 2003
13 October 2004
04 November 2005
11 December 2003
24 July 2003
WO 0194317 A2
13 December 2001
AU 6659601 A
US 2002077483 A1
WO 0194317 A2
17 December 2001
20 June 2002
13 December 2001
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
11 February 2020
Date of mailing of the international search report:
20 February 2020
Authorized officer:
Sahagún Krause, H
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E